These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18463960

  • 1. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [Abstract] [Full Text] [Related]

  • 2. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
    Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J.
    Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S, Takeda S, Nakajima M, Nishiyama M, Kitahara M, Shindou Y, Michihisa I, Abe T, Yoshino S, Hazama S, Nagano H.
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [Abstract] [Full Text] [Related]

  • 5. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C.
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [Abstract] [Full Text] [Related]

  • 6. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H.
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
    Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J.
    Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
    [Abstract] [Full Text] [Related]

  • 8. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 9. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [Abstract] [Full Text] [Related]

  • 10. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Matsumura S, Iwahashi M, Yamaue H.
    Dis Esophagus; 2017 Feb 01; 30(2):1-7. PubMed ID: 26725778
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
    Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N.
    Dis Esophagus; 2008 Feb 01; 21(6):496-501. PubMed ID: 18840134
    [Abstract] [Full Text] [Related]

  • 12. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T, Ojima H, Fukuchi M, Sakai M, Sohda M, Tanaka N, Suzuki S, Ieta K, Saito K, Sano A, Yokobori T, Inose T, Nakajima M, Kato H, Kuwano H.
    Ann Surg Oncol; 2015 Oct 01; 22(11):3653-8. PubMed ID: 25691281
    [Abstract] [Full Text] [Related]

  • 13. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.
    Hepatogastroenterology; 2008 Oct 01; 55(86-87):1631-5. PubMed ID: 19102357
    [Abstract] [Full Text] [Related]

  • 14. Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.
    Wang M, Gu J, Wang HX, Wu MH, Li YM, Wang YJ.
    Asian Pac J Cancer Prev; 2012 Oct 01; 13(8):4153-6. PubMed ID: 23098537
    [Abstract] [Full Text] [Related]

  • 15. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y, Kawada K, Tokairin Y, Hoshino A, Okada T, Kawano T.
    Dig Surg; 2018 Oct 01; 35(2):131-137. PubMed ID: 28554183
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.
    Lancet Oncol; 2018 Aug 01; 19(8):1094-1106. PubMed ID: 30042063
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of Combination Chemotherapy With Docetaxel, Nedaplatin, and 5-Fluorouracil for Advanced and Recurrent Esophageal Cancer.
    Sohda M, Hara K, Kuriyama K, Tateno K, Uchida S, Watanabe T, Shibasaki Y, Saito H, Nakazawa N, Sano A, Sakai M, Yokobori T, Ogawa H, Shirabe K, Saeki H.
    Anticancer Res; 2024 Mar 01; 44(3):1309-1315. PubMed ID: 38423646
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Iwahashi M, Yamaue H.
    Anticancer Res; 2016 Feb 01; 36(2):829-34. PubMed ID: 26851048
    [Abstract] [Full Text] [Related]

  • 19. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
    Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M, Doki Y.
    Oncology; 2011 Feb 01; 80(5-6):307-13. PubMed ID: 21778771
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K.
    Cancer Sci; 2016 Jun 01; 107(6):764-72. PubMed ID: 27061001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.